





# GONADAL HORMONES




# BIOSYNTHETIC PATHWAYS OF ESTROGENS




# BIOSYNTHETIC PATHWAYS OF ESTROGENS




# NATURAL ESTROGENS



ESTRADIOL




ESTRONE



ESTRIOL

# ESTROGENS

- Estrogens include the natural hormones as well as semi-synthetic and synthetic (stilbene) agents
- Estrogens are used as hormone-replacement therapy (menopause), in oncology and as contraceptives
- Most estrogen in the female is produced in the ovaries by the theca interna and the granulosa cells of the follicles



# ACTIONS OF ESTROGENS

- on sexual organs (primary and secondary sexual characteristics)
  - ovaries: stimulate follicular growth; small doses cause an increase in weight of ovary; large doses cause atrophy
  - uterus: endometrial growth
  - vagina: cornification of epithelial cells with thickening and stratification of epithelium
  - cervix: increase of cervical mucous with a lowered viscosity (favoring sperm access)
  - breast: cause enlargement of the breasts, shaping the body contours and the skeleton
  - Induces the growth of axillary and pubic hair and pigmentation of the genital tract.

# ACTIONS OF ESTROGENS

- Development and maintenance of internal (fallopian tubes, uterus, vagina), and external genitalia
- skin: increase in vascularization, development of soft, textured and smooth skin
- bone: increase osteoblastic activity
- electrolytes: retention of  $\text{Na}^+$ ,  $\text{Cl}^-$  and water by the kidney
- cholesterol: hypocholesterolemic effect





# METABOLIC EFFECTS OF ESTROGENS

- Decrease stromal cell production of IL-1, IL-6, TNFalpha
- Increase the production of Insulin-like growth factor (IGF)-1, bone morphogenic protein (BMP)-6 and transforming growth factor (TGF)-beta which are antiresorptive.
- Increase osteoblast production of the cytokine osteoprotegrin (OPG). OPG antagonizes the binding of osteoprotegrin-ligand to its receptor (termed RANK, or receptor activator of **NF-Kappa B**) and prevents the differentiation of osteoclast precursors to mature osteoclasts.
- Estrogens increase the osteoclast apoptosis.
- Estrogen affects bone growth and epiphyseal closure in both sexes.

# EFFECT ON LIPID METABOLISM AND COAGULATION

- Elevates HDL and decreases LDL and Lp(a)
- Alter bile composition by increasing cholesterol secretion and decreasing bile acid secretion. → Gallstone formation.
- Estrogens increase plasma levels of CBG, TBG, SSBG.
- Cause an increase in coagulation factor VII and XII. Decrease the anticoagulation factors protein C, protein S and antithrombin III. → Thrombosis
- Increase the fibrinolysis.
- In high concentration have antioxidant activity.
- Long-term administration of estrogens decrease the plasma renin, ACE, ET-1 production.
- Increase production of nitric oxide in the vascular wall.
- Increase melanin cc in the skin (chloasma gravidarum)

# ESTROGEN RECEPTORS



# NATURAL ESTROGENS

- Conjugated estrogenic substances:
  - an amorphous preparation containing water soluble conjugated forms of mixed estrogens from the urine of pregnant mares (Premarin, Cenestin - synthetic conjugated estrogens)
- estradiol :
  - oral : Estrace
  - transdermal: Climara, Alora, Vivelle, Vivelle-Dot, Estraderm, FemPatch

# NATURAL ESTROGENS

- estrone:
  - Kestrone 5 (injectable only)
- esterified estrogen
  - (75-85% sodium estrone sulfate and 6- 15% sodium equilin sulfate)
  - Estratab; Menest
- estropipate (piperazine estrone sulfate)
  - Ogen; Ortho-Est

# NATURAL ESTROGENS

- Sustained-release injectables:
  - estradiol valerate in oil (Delestrogen; Valergen)
  - estradiol cypionate in oil (depGynogen; DepoGen)
  - duration of action from 3 to 8 weeks
  - esterified at C-17 hydroxyl group

# ESTROGEN PRODUCTS IN HUNGARY

## ■ Estradiol

- Dermestril
- Divigel
- Estrimax
- Estrofem
- Linoladiol
- Vagifem



## ■ Estriol

- Estrokad
- Ortho-Gynest D
- Ovestin

## ■ Tibolon

- Livial



# ESTROGEN PRODUCTS



868\* 0.3 mg



867\* 0.625 mg



864\* 0.9 mg



866\* 1.25 mg



865\* 2.5 mg

**†Premarin®**  
(conjugated estrogens, USP)




0.75 mg



1.5 mg



3 mg  
tablets



vaginal cream

**Ogen®**  
(estropipate)



# ESTROGEN PRODUCTS



**1014\*** 0.3 mg



**1022\*** 0.625 mg



**1024\*** 1.25 mg



**1025\*** 2.5 mg

**ESTRATAB®**  
(esterified estrogens tablets, USP)



0.5 mg



1 mg



2 mg

**Estrace®**  
(estradiol tablets, USP)




**1026\***

**ESTRATEST®**  
(esterified estrogens, USP 1.25 mg and  
methyltestosterone, USP 2.5 mg)



**1023\***

**ESTRATEST® H.S.**  
(esterified estrogens, USP 0.625 mg and  
methyltestosterone, USP 1.25 mg)



25µg

# VAGIFEM®

*estradiol vaginal tablets*


**CONVENIENT, COMFORTABLE  
RELIEF WITHOUT THE MESS**




1 1/2 oz tube

**Estrace® Vaginal Cream**  
(estradiol vaginal cream USP, 0.01%)

# DIETHYLSTIBESTROL



**DIETHYLSTILBESTROL (DES)**



- Synthesized in 1938.
- From about 1940 to 1970, DES was given to pregnant women under the mistaken belief it would reduce the risk of pregnancy complications and losses.
- In 1971, DES was shown to cause a rare vaginal tumor (adenocarcinoma) in girls and women who had been exposed to this drug in utero.
- In male babies: testicular hypoplasia, cryptorchism, epididymal cysts.
- Breast cancer development in the mothers.

# THERAPEUTIC USE OF ESTROGENS

1. Hormone replacement therapy: Conjugated estrogens: 0.625 mg/day for replacement (oral potency is lower than ethinyl estradiol. Means around 5-10 µg.)
2. Contraceptive: Ethinyl estradiol (EOD): 20-35 µg/day
3. Postmenopausal hormone-replacement therapy: prevention of bone loss and amelioration of vasomotor systems.
4. Vasomotor symptoms: hot flashes may alternate with chilly sensations, inappropriate sweating and paresthesias. Instead of estrogen medroxyprogesterone acetate can be administered.
5. Prevention of cardiovascular diseases, but thrombembolic disease and the incidence of gallstones are increased.
6. Neuroprotective effect: Delay the onset of Alzheimer's disease. The trial result is controversial.
7. Urogenital atrophy: dryness and itching of the vagina, pain during urination and intercourse, a need to urinate urgently and often, incontinence. Estrogen orally, vaginal cream, ring device.
8. Treatment of testosterone-dependent prostate carcinoma

# SERMS – SELECTIVE ESTROGEN-RECEPTOR MODULATORS

- Clomiphen (Clomid, Omiphin), exception!!
- Tamoxifen
- Toremifen (Fareston)
- Raloxifen (Evista)
- Centchroman/Ormeloxifene (Saheli, Novex-DS, Centron, Sevista)
- Under development
  - Droloxifen
  - Idoxifen
  - Nafoxiden
- Common feature: variable actions depending on target tissue:
  - Agonist in bone
  - Partial agonist in endometrium
  - Antagonist in breast






# CLOMIPHENE CITRATE

Adverse effects:

- vasomotor flushes (or hot flashes )
- abdominal discomfort
- visual blurring (dose-dependent)
- reversible ovarian enlargement and cyst formation
- twin formation!!!



CLOMIPHENE (CLOMID)


Fertility pill!!!



## Pharmacodynamics of Clomiphene Citrate

### Primary Site of Action

Binds to estrogen receptors in ovaries




Hypothalamus perceives hypoestrogenic state

Pituitary increases release of gonadotropins


### Secondary Site of Action

Direct effect on ovaries



# TAMOXIFEN

- Tamoxifen competitively binds to ER (on tumors)
- Nonsteroidal
- Causes cells to remain in the G0 and G1 phases
- Cytostatic rather than cytocidal
- Prodrug (2D6, 3A4)
- Side effects:
  - Bone
  - Cardiovascular and metabolic
  - CNS
  - Premature growth plate fusion
  - Agonist at bone
  - Partial agonist at uterus (cancer risk)
  - Antagonist at breast




**TAMOXIFEN (NOLVADEX)**



# RALOXIFENE (EVISTA)

- Agonist at bone
- Antagonist at breast and uterus
- no increased cancer risk
- Known as a SERM (selective estrogen receptor modulator)
- currently used to modify/prevent postmenopausal osteoporosis



RALOXIFENE (EVISTA)






# ESTROGEN RECEPTOR ANTAGONISTS

- Fulvestrant (Faslodex)
  - 30 x stronger than tamoxifen
  - Ind: breast cancer



# STEROID AROMATASE




Estrogens


# AROMATASE INHIBITORS

- Aromatase is a cytochrome P450 enzyme that catalyzes the conversion of adrenal androgen androstenedione to estrone in both pre- and post menopausal women
- Reaction occurs in the liver, muscle, adipose and breast tissue
- In post-menopausal women, aromatization is responsible for the majority of circulating estrogen
- Aminoglutethimide was used but has now been replaced by more selective drugs
- Drugs may be steroidal (formestan, exemestane) or non-steroidal (anastrozole, letrozole, vorozole)
- Estrogen deprivation through aromatase inhibition is an effective and selective treatment for some post-menopausal patients with hormone-dependent breast cancer
- Second line drugs in the treatment of breast cancer

# AROMATASE INHIBITORS



**ANASTROZOLE (ARIMIDEX)**




**LETROZOLE (FEMARA)**

- both of these drugs are used in the treatment of advanced
- breast cancer in post-menopausal women with disease
- progression following tamoxifen therapy

# EXEMESTANE (AROMASIN)

- 6-methylenandrosta-1,4-diene-3,17-dione
- structurally related to androstenedione
- acts as an irreversible (suicide) inhibitor of aromatase
- has no effect on other enzymes involved in steroidogenesis
- indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy




EMESTANE (AROMASIN)




# QUINESTROL

- is a prodrug of ethinylestradiol (EE), with no estrogenic activity of its own
- used in menopausal hormone therapy
- hormonal birth control
- to treat breast cancer and prostate cancer
- very long biological half-life of more than 120 hours (5 days)





# SEMI-SYNTHETIC ESTROGENS

- Very commonly utilized in oral contraceptive products
- ethinyl estradiol is more potent than mestranol



ETHINYL ESTRADIOL



MESTRANOL

# PROGESTERONE AND PROGESTINS

- Drugs which mimic the action of progesterone
- complement the action of estrogen on primary and secondary sex characteristics
- many are used as oral contraceptives:
  - norgestrel, levonorgestrel, norethindrone, norethindrone acetate, norethynodrel, ethynodiol diacetate, desogestrel and norgestimate



# EFFECTS OF PROGESTINS

## Reproductive tract

- Decreases the frequency of the hypothalamic pulse generator.
- Endocervical glands: scant, viscid material, helps to block the penetration of sperms.
- Suppress menstruation and uterine contractility.
- Breakthrough bleeding can occur!

## Mammary Gland

- With estrogen causes the proliferation of the acini of mammary gland.

## CNS effects


- At midcycle the body core temperature is elevated by 0.5 C°. → ovulation. Temperature increase is persists until the onset of menstruation.
- Depressant and hypnotic effect.

## Metabolic effects

- Increase the basal insulin level. Long-term administration of potent progestins (norgestrel) **decrease glucose tolerance.**
- Increase LPL and fat deposition. Increase LDL level.
- **↓ HDL and ↑ LDL**
- **Hirsutism and acne (androgenic effect)**


# PROGESTERONE

- Natural hormone secreted
- by the corpus luteum and the
- placenta ( a C-21 steroid).
- It is also an important intermediate in steroid biogenesis in all tissues that produce steroids (testes, adrenal cortex).
- Intestinal absorption is quite erratic; must be micronized for
- most effective absorption (Prometrium)




**PROGESTERONE**

## Schematic representation of progesterone receptor binding and transactivation




# 19-NOR STEROIDS

- Chemical analogues of testosterone - some retain some
- androgenic activity such as norethindrone




**NORETHINDRONE**




**NORETHINODREL**

## 19-NOR STEROIDS




**NORGESTREL**




**NORGESTIMATE**

## 19-NOR STEROIDS



**DESOGESTREL**




**ETHYNODIOL DIACETATE**

- Devoid of androgenic and anti-estrogenic activities!!!

# 19-NOR STEROIDS


- Both the racemic and the optically pure (levonorgestrel) are used in oral contraceptive products



**NORGESTREL**

# ETONORGESTREL

- Vaginal rings
- provide controlled release of drugs for intravaginal administration over extended periods of time.
- self-administered once a month
- leaving the ring in for three weeks
- slowly releases hormones into the body




**ETONORGESTREL (NUVARING)**




# 19-NOR STEROIDS

- Some 19-nor steroids can be metabolized to estrogenic compounds
- these progestins then exhibit estrogenic activity
  - norethynodrel and ethynodiol diacetate have estrogenic activity

# 17-HYDROXY ESTERIFIED PROGESTINS



**MEDROXYPROGESTERONE ACETATE**




**HYDROXYPROGESTERONE CAPROATE**

- Medroxyprogesterone acetate is a very popular orally effective progestin (Provera)

# PROGESTINS AVAILABLE IN HUNGARY

- Medroxyprogesterone (PROVERA)
- Progesterone (CRINONE, UTROGESTAN)
- Dydrogesterone (DUPHASTON)
- Norethisterone (NORCULUT)



# COMBINED ESTROGENS AND PROGESTINS

- Currently very popular forms for HRT
- combine an estrogen (natural or semi-synthetic) with an orally effective progestin
  - Prempro and Premphase
  - FemHRT
  - Combipatch



# GONADOTROPINS FOR OVULATION STIMULATION (DRUGS IN HUNGARY)

- Chorionic gonadotrophin (CHORAGON, PREGNYL)
- Human menopausal gonadotrophin (MENOPUR, MERIONAL)
- Urofollitropin (FOSTIMON)
- Follitropin alpha (GONAL)
- Follitropin beta (PUREGON)
- Lutropin (LUVERIS)
- Choriogonadotropin alpha (OVITRELLE)
- Corifollitropin alpha (ELONVA)

# PROGESTIN ANTAGONIST

## ■ Mifepristone

- Glucocorticoid receptor antagonist as well
- Abortifacient (used with PGs)